CHE vs REGN · P/E 24, rev $2.43B vs P/E 14, rev $14.34B
Chemed Corp (CHE) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Chemed Corp (CHE) is a medical care facilities company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CHE revenue for 2024-12-31 was $2.43B. Net income was $302.0M. Revenue was up 7.4% from 2023-12-31 to 2024-12-31. CHE currently screens at market cap $5.79B and trailing P/E 23.8.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CHE currently screens at market cap $5.79B and trailing P/E 23.8. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CHE and REGN stock pages for the full models.
Not investment advice.